IQV · IQVIA Holdings

223 filings

IQV SEC Filings

IQVIA Holdings - 223 total filings

Filing record · 2016–202610-K1110-Q338-K130

Showing 1–50 of 223 filings

IQVIA Holdings Quarterly Report for Q3 Ended Sep 30, 2026

IQVIA Holdings Inc. reported third-quarter 2026 revenues of $4,428 million, up from $4,100 million in the third quarter of 2025, and net income attributable to IQVIA Holdings Inc. of $350 million versus $331 million a year earlier. Diluted EPS was $2.10 compared with $1.93. For the first nine months, revenues were $12,947 million (versus $11,946 million) and diluted EPS was $5.24 (versus $4.86). Income from operations for the nine months was $1,592 million, and restructuring costs rose to $150 million from $81 million. The company describes constant currency revenue growth of approximately 8.6% in the third quarter, with Research & Development Solutions contributing a $221 million increase and Commercial Solutions a $132 million increase. Cash and cash equivalents rose to $2,249 million at September 30, 2026, from $1,980 million at December 31, 2025, while total debt principal reached $16,172 million, up from $15,800 million. During 2026 the company issued €950 million of 4.625% senior notes due 2033 and $2,000 million of 6.375% senior notes due 2034, and repaid its $650 million Term Loan due 2027 and the €550 million 1.750% Notes. Nine-month operating cash flow was $2,001 million, and the company repurchased $950 million of common stock, leaving $2,819 million remaining under its Repurchase Program after the Board increased total authorization to $15,725 million in May 2026. The company reorganized its reporting into two segments, Commercial Solutions and Research & Development Solutions, effective January 1, 2026. Research & Development Solutions' contracted backlog was $32.6 billion at September 30, 2026, down from $34.0 billion at year-end 2025, reflecting a $2.1 billion reduction from refined backlog criteria for inactive trials. Total remaining performance obligations were approximately $34.2 billion.

Oct 27, 2026 8-K

IQVIA Holdings 8-K Report, Financial Results (Oct 27, 2026)

IQVIA Holdings Inc. reported record third-quarter 2026 results, with revenue of $4,428 million, up 8.0% year-over-year (8.6% at constant currency). GAAP net income was $350 million and GAAP diluted EPS was $2.10. Adjusted EBITDA rose to $1,032 million, up 8.7%, and Adjusted Diluted EPS was $3.34, up 11.3%. R&D Solutions net new bookings reached $3.2 billion, up 15%, with a book-to-bill ratio of 1.2x. Management cited favorable demand indicators and said its organic growth acceleration was double the prior rate for Commercial Solutions and nearly triple for clinical. The company also adjusted R&DS contracted backlog following a review of inactive trials. The backlog adjustment was approximately $2.1 billion and, per the filing, had no impact on historical financial results, 2026 guidance, book-to-bill, or next-twelve-month revenue from backlog. R&DS contracted backlog stood at $32.6 billion as of September 30, 2026, with approximately $9.4 billion expected to convert to revenue in the next twelve months, representing 10% year-over-year growth. IQVIA raised its full-year 2026 guidance for revenue to $17,350 million–$17,500 million, Adjusted EBITDA to $4,025 million–$4,055 million, and Adjusted Diluted EPS to $12.90–$13.00. Net debt was $13,818 million and the Net Leverage Ratio was 3.45x trailing twelve-month Adjusted EBITDA. Free cash flow for the quarter was $667 million, equal to 120% of Adjusted Net Income. The company will hold an Investor Day on December 1, 2026.

Oct 27, 2026 8-K

IQVIA Holdings 8-K Report, Material Agreement (Sep 23, 2026)

On September 23, 2026, IQVIA Inc., a wholly owned subsidiary of IQVIA Holdings Inc., completed the issuance and sale of $2.0 billion in gross proceeds of 6.375% senior notes due 2034. The notes were issued under an indenture dated the same day among the Issuer, U.S. Bank Trust Company, National Association, as trustee, and certain subsidiaries of the Issuer as guarantors. The notes are unsecured obligations of the Issuer and mature on March 15, 2034, unless earlier repurchased or redeemed. The filing states that the net proceeds will be used to redeem in full the Issuer's Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer's revolving credit facility, and to pay fees and expenses related to the offering. This refinancing replaces existing debt, including a revolver balance, with longer-dated fixed-rate notes. Interest is payable semi-annually on March 15 and September 15, beginning March 15, 2027. The Issuer may redeem the notes before maturity at a customary make-whole premium at any time before September 15, 2029, subject to a customary equity claw redemption right. After that date, the redemption premium declines from 3.188% to 0.000%. The indenture is filed as Exhibit 4.1, and the filing incorporates the description of the notes under Item 2.03 as well.

Sep 23, 2026 8-K

IQVIA Holdings 8-K Report, Corporate Update (Sep 9, 2026)

IQVIA Holdings Inc. (NYSE: IQV) disclosed on September 9, 2026 that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise $2,000,000,000 in gross proceeds through an offering of senior notes due 2034 and priced the offering. The Issuer entered into a purchase agreement with the representative of the purchasers for $2.0 billion in aggregate principal amount of senior notes bearing interest at 6.375% per annum. The company states that the net proceeds will be used to redeem in full the Issuer's Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer's revolving credit facility, and to pay fees and expenses related to the offering. The notes will pay interest semi-annually on March 15 and September 15, beginning March 15, 2027, and will mature on March 15, 2034. Closing is expected on or about September 23, 2026, subject to customary closing conditions. The notes are being offered in reliance on Rule 144A and Regulation S and have not been registered under the Securities Act. The filing is a refinancing and debt-management transaction that replaces the 5.000% notes due 2026 and reduces revolving credit facility borrowings.

Sep 9, 2026 8-K

IQVIA Holdings 8-K Report, Financial Results (Jul 28, 2026)

IQVIA Holdings Inc. furnished an 8-K under Item 2.02 on July 28, 2026, attaching a press release reporting results for the second quarter ended June 30, 2026. Revenue was $4,368 million, up 8.7% year-over-year on a reported basis, with GAAP net income of $256 million, GAAP diluted EPS of $1.53, Adjusted EBITDA of $994 million (up 9.2%), and Adjusted Diluted EPS of $3.15 (up 12.1%). R&D Solutions net new bookings were $3.15 billion, up 19% year-over-year, with a 1.22x book-to-bill ratio. Results are presented under the company's new two-segment structure, Commercial Solutions and Research & Development Solutions, effective January 1, 2026. Management raised full-year 2026 guidance for revenue to $17,275 million to $17,475 million, Adjusted EBITDA to $4,000 million to $4,050 million, and Adjusted Diluted EPS to $12.80 to $13.00. The filing attributes the revenue raise to approximately 100 basis points higher organic growth and about 50 basis points higher M&A contribution, partly offset by roughly 80 basis points of unfavorable foreign exchange versus prior guidance. Balance sheet metrics show cash of $1,909 million, debt of $15,999 million, net debt of $14,090 million, and a Net Leverage Ratio of 3.59x trailing twelve-month Adjusted EBITDA. Second-quarter operating cash flow was $558 million and free cash flow was $360 million. The company repurchased $398 million of stock in the quarter, with $2,819 million of authorization remaining as of June 30, 2026.

Jul 28, 2026 10-Q

IQVIA Holdings Quarterly Report for Q2 Ended Jun 30, 2026

IQVIA Holdings Inc. reported second-quarter 2026 revenues of $4,368 million, up from $4,017 million a year earlier, with an 8.7% increase. Constant currency revenue growth was approximately $343 million, or 8.5%. Income from operations was flat at $506 million, as higher cost of revenues, SG&A and restructuring costs offset revenue growth. Net income attributable to IQVIA Holdings Inc. was $256 million, or $1.53 per diluted share, compared with $266 million, or $1.54 per diluted share, in the prior-year quarter. For the first six months of 2026, revenues were $8,519 million, up 8.6%, and net income attributable to the company was $530 million, or $3.14 per diluted share. The company generated $1,176 million of operating cash flow in the first six months of 2026, compared with $1,011 million a year earlier. It repurchased $950 million of common stock during the period and, on May 7, 2026, increased its repurchase authorization by $2,000 million to a total of $15,725 million, with $2,819 million remaining as of June 30, 2026. Total indebtedness was $16,081 million at June 30, 2026, against cash of $1,909 million. In June 2026 the company issued €950 million of 4.625% senior notes due 2033 and used the proceeds to repay its $650 million Term Loan due 2027 and part of its revolving credit facility. Restructuring costs rose to $63 million in the second quarter from $32 million, and $114 million for the six months from $61 million. Segment profit grew in both segments, with Commercial Solutions profit up 10.6% and Research & Development Solutions profit up 11.2% for the quarter. The backlog of Research & Development Solutions was $34.2 billion at June 30, 2026, with approximately $9.2 billion expected to convert to revenue over the next twelve months.

Jul 28, 2026 8-K

IQVIA Holdings 8-K Report, Material Agreement (Jun 11, 2026)

On June 11, 2026, IQVIA Inc., a wholly owned subsidiary of IQVIA Holdings Inc., completed the issuance and sale of €950,000,000 in gross proceeds of 4.625% senior notes due 2033. The Notes were issued under an Indenture dated June 11, 2026, among IQVIA Inc., U.S. Bank Trust Company, National Association, as trustee, and certain subsidiaries of the Issuer as guarantors. The Notes are unsecured obligations of the Issuer and bear interest payable semi-annually on June 15 and December 15, beginning December 15, 2026. The net proceeds will be used to refinance certain of the Issuer's existing indebtedness and to pay fees and expenses related to the offering. The filing also states the Issuer may redeem the Notes before their June 15, 2033 maturity, subject to a customary make-whole premium at any time before June 15, 2029 (with a customary equity claw redemption right), and thereafter at a redemption premium declining from 2.313% to 0.000%. The filing is limited to the debt issuance itself, reported under Item 1.01 (Material Definitive Agreement) and Item 2.03 (Direct Financial Obligation), with the Indenture filed as Exhibit 4.1.

Jun 11, 2026 8-K

IQVIA Holdings 8-K Report, Corporate Update (Jun 4, 2026)

IQVIA Holdings Inc. (NYSE: IQV) reported in this Form 8-K, filed June 4, 2026, that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), priced an offering of €950,000,000 in aggregate principal amount of senior notes due 2033. The notes bear interest at 4.625% per annum, payable semi-annually in arrears on June 15 and December 15, beginning December 15, 2026, and mature on June 15, 2033, unless earlier repurchased or redeemed. The Issuer entered into a purchase agreement with the representative of the purchasers named therein, and closing is expected on or about June 11, 2026, subject to customary closing conditions. According to the attached pricing press release (Exhibit 99.1), proceeds will be used to refinance certain of the Issuer's existing indebtedness and to pay fees and expenses related to the offering. The notes have not been registered under the Securities Act and are being offered only to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S, by means of a private offering memorandum. For investors, the filing is a debt financing and refinancing event rather than an operating or earnings update. The filing identifies the completion of the offering as contingent on customary closing conditions, and its forward-looking statements cite the failure to consummate the offering and changes in market conditions as risk factors.

Jun 4, 2026 8-K

IQVIA Holdings 8-K Report, Corporate Update (Jun 3, 2026)

IQVIA Holdings Inc. (NYSE: IQV) disclosed in a Form 8-K filed June 3, 2026 that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise €950,000,000 in gross proceeds through an offering of senior notes due 2033. The offering is intended to refinance certain of the Issuer's existing indebtedness and to pay fees and expenses related to the offering. The filing is a notice of intent under Item 8.01 (Other Events) and attaches a launch press release as Exhibit 99.1. The press release states that completion of the offering is subject to market and other customary conditions, so the timing and final size of the issuance are not confirmed in this filing. The notes are being offered under Rule 144A to qualified institutional buyers in the United States and under Regulation S outside the United States, and have not been registered under the Securities Act of 1933. For investors, the key takeaway is a planned refinancing of existing debt at the Issuer level, denominated in euros, with a 2033 maturity. The filing does not disclose the coupon, pricing, or the specific debt being refinanced. The press release notes that the offering's failure to close is a forward-looking risk.

Jun 3, 2026 8-K

IQVIA Holdings 8-K Report, Corporate Update (May 7, 2026)

IQVIA Holdings Inc. (IQV) filed a Form 8-K on May 7, 2026 to disclose that its board of directors authorized the repurchase of an additional $2,000 million of the company's common stock under its existing equity repurchase program (the "Repurchase Program"). The filing states this brings the total remaining authorization to $3,217 million, which the accompanying press release rounds to $3.2 billion. The filing emphasizes that the Repurchase Program does not obligate the company to buy any particular amount of stock and may be modified, extended, suspended or discontinued at any time. Timing and amount of repurchases are set by management based on factors including the market price of the stock, corporate requirements and overall market conditions. Purchases may occur in open market transactions through a broker-dealer, in block trades, or in privately negotiated transactions, and the program has no expiration date. The company also states that it has, from time to time, repurchased shares through private or other transactions outside the Repurchase Program, and that it may discontinue repurchases without notice. The press release, filed as Exhibit 99.1, is titled "IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization" and describes IQVIA as a global provider of clinical research services, commercial insights and healthcare intelligence.

May 7, 2026 8-K

IQVIA Holdings 8-K Report, Financial Results (May 5, 2026)

IQVIA Holdings Inc. (NYSE: IQV) furnished its press release reporting first-quarter 2026 results for the quarter ended March 31, 2026, under Item 2.02 of Form 8-K. Revenue was $4,151 million, up 8.4% on a reported basis and 6.0% at constant currency. GAAP net income attributable to IQVIA was $274 million, or $1.61 per diluted share, and Adjusted EBITDA was $932 million, up 5.5% year-over-year. Adjusted diluted EPS was $2.90, up 7.4%. Commercial Solutions revenue grew 11.6% on a reported basis to $1,754 million, while R&D Solutions revenue rose 6.2% to $2,397 million. The company now reports two segments, Commercial Solutions and Research & Development Solutions, following a reorganization effective January 1, 2026. R&DS contracted backlog stood at $34.2 billion at quarter-end, with net new bookings of $2.5 billion and a book-to-bill ratio of 1.04x for the quarter. The company expects approximately $8.9 billion of backlog to convert to revenue in the next twelve months. Operating cash flow was $618 million and free cash flow was $491 million, up 15% year-over-year. IQVIA repurchased $552 million of common stock in the quarter and had $1,217 million of authorization remaining. Net debt was $13,886 million, and the Net Leverage Ratio was 3.62x trailing twelve-month Adjusted EBITDA. For full-year 2026, IQVIA reaffirmed revenue guidance of $17,150 million to $17,350 million and Adjusted EBITDA guidance of $3,975 million to $4,025 million, and raised Adjusted Diluted EPS guidance to $12.65 to $12.95. Revenue guidance assumes about 150 basis points of acquisition contribution and an approximately 100 basis point foreign exchange tailwind.

May 5, 2026 10-Q

IQVIA Holdings Quarterly Report for Q1 Ended Mar 31, 2026

IQVIA Holdings Inc. reported first-quarter 2026 revenues of $4.151 billion, up from $3.829 billion in the first quarter of 2025, an increase of $322 million or 8.4%. Income from operations rose to $514 million from $496 million, and net income attributable to IQVIA Holdings Inc. was $274 million, compared with $249 million a year earlier. Diluted earnings per share were $1.61, versus $1.40. Growth was led by Commercial Solutions, whose revenues rose 11.6% to $1.754 billion, while Research & Development Solutions revenues rose 6.2% to $2.397 billion. Constant currency revenue growth was approximately 6.0% for the company as a whole. Restructuring costs increased to $51 million from $29 million, and the filing states that restructuring actions are expected to continue through 2026 and into 2027. Cash flow and capital allocation were active during the quarter. Net cash provided by operating activities was $618 million, up from $568 million. The company repurchased 3.2 million shares for $552 million under its Repurchase Program, leaving $1.217 billion of remaining authorization as of March 31, 2026. Total debt principal was $15.908 billion, and the company repaid its €550 million 1.750% notes due 2026 using a $650 million Term Loan due 2027. Cash and cash equivalents were $1.947 billion at quarter-end, against $1.980 billion at December 31, 2025. Total stockholders' equity was $6.349 billion. Backlog for Research & Development Solutions was $34.2 billion, and the company expects approximately $8.9 billion of it to convert to revenue over the next twelve months. The filing reports no material changes to risk factors, critical accounting policies, or market risk disclosures compared with the 2025 Form 10-K. The company also reorganized its reportable segments effective January 1, 2026 into Commercial Solutions and Research & Development Solutions. Management concluded that disclosure controls were effective, and it expects its available cash, operating cash flows and revolving credit access to fund operations for at least the next 12 months.

May 5, 2026 8-K

IQVIA Holdings 8-K Report, Executive Changes (Apr 23, 2026)

On April 23, 2026, IQVIA Holdings Inc. held its 2026 Annual Meeting of Stockholders, where stockholders approved the IQVIA Holdings Inc. 2026 Incentive and Stock Award Plan (the "2026 Plan"). The 2026 Plan took effect immediately upon approval and replaces the 2017 Incentive and Stock Award Plan (the "2017 Plan"), with any shares remaining under the 2017 Plan assumed by the 2026 Plan. It authorizes stock options (incentive and non-qualified), stock appreciation rights, restricted stock awards, restricted stock units, and stock awards. Performance-based awards vest based on metrics set by the Leadership Development and Compensation Committee, which may include revenue, adjusted EBITDA, earnings per share, adjusted diluted earnings per share, cash flow, free cash flow as a percentage of adjusted net income, and relative total stockholder return. The Committee also approved new forms of award agreements for stock appreciation rights, performance shares, restricted stock units, and cash-settled restricted stock units for use under the plan. At the meeting, stockholders elected nine directors to one-year terms, ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026, and approved, on an advisory basis, the 2025 compensation of the named executive officers. Stockholders did not approve the advisory proposal concerning separate Chairman and Chief Executive Officer roles, which received 36,717,802 votes for and 111,154,252 votes against. The record date share count was 167,866,339 shares of common stock. The 2026 Plan's material terms are described in the company's definitive proxy statement filed February 27, 2026. The full plan and the forms of award agreements are filed as Exhibits 10.1 through 10.5 to this Form 8-K.

Apr 23, 2026 10-K

IQVIA Holdings Annual Report, Year Ended Dec 31, 2025

IQVIA Holdings Inc. (IQV) reported 2025 revenues of $16.31 billion, up 5.9% from $15.41 billion in 2024, with income from operations of $2.18 billion and diluted EPS of $7.84 compared with $7.49 in 2024. Technology & Analytics Solutions revenue rose 7.6% to $6.63 billion, and Research & Development Solutions revenue rose 4.3% to $8.90 billion, while its segment profit fell 3.9% to $1.87 billion. Management described 2025 as a year in which macroeconomic uncertainty slowed client decision-making. Contracted R&D backlog grew to $32.7 billion, and total remaining performance obligations were approximately $34.2 billion. Cash flow from operations was $2.65 billion, and the company spent $1.71 billion, net of cash, on acquisitions across all three segments. Total indebtedness was $15.80 billion at year end, including the $2.0 billion 6.250% senior notes due 2032 issued in June 2025. The company repurchased 7.4 million shares for $1.24 billion during the year, and $1.77 billion remained under its repurchase authorization at December 31, 2025. Starting January 1, 2026, IQVIA will report two segments, Commercial Solutions and Research & Development Solutions, with Contract Sales & Medical Solutions folded into Commercial Solutions and certain Real-World offerings moved to R&D Solutions. Restructuring costs rose to $105 million in 2025, and the company expects restructuring actions to continue through 2026.

Feb 17, 2026 8-K

IQVIA Holdings 8-K Report, Financial Results (Feb 5, 2026)

IQVIA Holdings Inc. (NYSE: IQV) furnished an 8-K on February 5, 2026 under Item 2.02 attaching a press release reporting preliminary, unaudited fourth-quarter and full-year 2025 results and full-year 2026 guidance. For Q4 2025, revenue was $4,364 million, up 10.3% reported and 8.1% at constant currency; GAAP net income was $514 million and GAAP diluted EPS was $2.99, while Adjusted Diluted EPS was $3.42 and Adjusted EBITDA was $1,046 million. For full-year 2025, revenue was $16,310 million, up 5.9% reported, GAAP net income was $1,360 million (down 0.9%), and Adjusted Diluted EPS was $11.92. Operating cash flow for 2025 was $2,654 million and free cash flow was $2,051 million, equal to 99% of Adjusted Net Income. R&D Solutions contracted backlog reached $32.7 billion, up 5.3% year-over-year, with a Q4 book-to-bill ratio of 1.18x. At year-end, cash was $1,980 million, debt was $15,724 million, net debt was $13,744 million, and the Net Leverage Ratio was 3.63x. The company repurchased $1,244 million of stock in 2025 and had $1,769 million of authorization remaining. For 2026, IQVIA guided to revenue of $17,150 million to $17,350 million, Adjusted EBITDA of $3,975 million to $4,025 million, and Adjusted Diluted EPS of $12.55 to $12.85. The guidance includes about 150 basis points of contribution from acquisitions, about 100 basis points of foreign exchange tailwind, and roughly $80 million of higher interest expense. Effective January 1, 2026, the company is reorganizing its segments: CSMS is folded into TAS, which is renamed Commercial Solutions, and Real-World Late Phase and certain other Real-World offerings move into R&DS. Segment recast figures for 2025 and 2024 are provided.

Feb 5, 2026 8-K

IQVIA Holdings 8-K Report, Material Agreement (Dec 9, 2025)

IQVIA Holdings Inc. filed a Form 8-K reporting that on December 9, 2025 it entered into Amendment No. 5 to its Fifth Amended and Restated Credit Agreement. The amendment refinances its Term A-1 Dollar Loans and Term A-2 Dollar Loans into a new class of term A dollar loans, refinances its Term A Euro Loans into a new class of term A euro loans, and refinances all current U.S., Japanese and Swiss/Multicurrency Revolving Credit Commitments into a new class of revolving credit commitments. The amendment also reduces the interest rate on U.S. dollar term A loans and U.S. dollar revolving credit loans by eliminating the term SOFR credit spread adjustment. In addition, it releases the Swiss Subsidiary Borrower and the Japanese Borrower from all obligations as borrowers under the Credit Agreement. The filing states that the Amendment is being reported under Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation). The filing does not state any dollar amounts, borrowing sizes or rate levels for the refinanced facilities. The full terms are in the Amendment, filed as Exhibit 10.1, with Bank of America, N.A. as administrative agent and collateral agent.

Dec 9, 2025 8-K

IQVIA Holdings 8-K Report, Executive Changes (Nov 5, 2025)

IQVIA Holdings Inc. filed this Current Report on Form 8-K dated November 5, 2025, to disclose the Board of Directors' appointment of William G. Kaelin Jr., M.D. to the Board on that date. The Board determined that Dr. Kaelin satisfies the New York Stock Exchange definition of "independent director." He will participate in the non-employee director compensation arrangements described in the company's proxy statement dated February 28, 2025, and is expected to enter into the company's standard indemnification agreement with non-management directors. The company also issued a press release announcing the appointment, furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). That press release describes Dr. Kaelin as a Senior Physician-Scientist at Brigham and Women's Hospital, Sidney Farber Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, and an Investigator at the Howard Hughes Medical Institute. It notes that he shared the 2019 Nobel Prize in Physiology or Medicine and that he serves on the board of Eli Lilly and Company, where he chairs the Science and Technology Committee. Chairman and CEO Ari Bousbib is quoted welcoming him to the board. The filing contains no financial results, guidance, or transaction disclosures. Its investor relevance is limited to board refreshment and the addition of an independent director with scientific and oncology expertise.

Nov 5, 2025 10-Q

IQVIA Holdings Quarterly Report for Q3 Ended Sep 30, 2025

IQVIA Holdings Inc. reported third-quarter 2025 revenues of $4.10 billion, up $204 million, or 5.2%, from $3.90 billion a year earlier, with constant currency revenue growth of approximately $150 million, or 3.9%. Income from operations was $553 million versus $550 million, while net income attributable to IQVIA Holdings Inc. rose to $331 million from $285 million. Diluted earnings per share were $1.93 compared with $1.55. For the first nine months of 2025, revenues were $11.95 billion, up 4.4%, and diluted EPS was $4.86 versus $5.08 a year earlier, as net income attributable to the company fell to $846 million from $936 million. Interest expense increased to $536 million for the nine months from $499 million, reflecting higher outstanding debt balances. The balance sheet and cash flow reflect active capital management. Total debt principal rose to $15.03 billion, including the issuance of $2.00 billion of 6.250% senior notes due 2032 in June 2025, and the current portion of long-term debt increased to $2.16 billion. The company repurchased 6.4 million shares for $1.03 billion during the nine months, leaving $1.98 billion of remaining authorization under the Repurchase Program. Net cash provided by operating activities was $1.92 billion for the nine months, compared with $1.83 billion a year earlier. Goodwill increased to $15.95 billion, largely from acquisitions and foreign currency effects, and the company reported total backlog for Research & Development Solutions of $32.4 billion. The company also disclosed that in August 2025 the parties to its long-running Veeva litigation reached a complete resolution of all pending legal disputes, with no payment made by either party. Management stated that it believed its disclosure controls and procedures were effective as of September 30, 2025, and that the company was in compliance in all material respects with its financial covenants.

Oct 28, 2025 8-K

IQVIA Holdings 8-K Report, Financial Results (Oct 28, 2025)

IQVIA Holdings Inc. filed this Form 8-K on October 28, 2025 to furnish its press release reporting results for the third quarter ended September 30, 2025. Third-quarter revenue was $4,100 million, up 5.2 percent on a reported basis and 3.9 percent at constant currency. GAAP net income attributable to IQVIA was $331 million, or $1.93 per diluted share, and Adjusted EBITDA was $949 million, up 1.1 percent year-over-year. Adjusted diluted EPS was $3.00. Free cash flow was $772 million, up 35 percent year-over-year, equal to 150 percent of Adjusted Net Income. By segment, Technology & Analytics Solutions (TAS) revenue was $1,631 million, up 5.0 percent reported, and Research & Development Solutions (R&DS) revenue was $2,260 million, up 4.5 percent reported. R&DS delivered $2.6 billion of quarterly bookings, a book-to-bill ratio of 1.15x, and contracted backlog of $32.4 billion, up 4.1 percent year-over-year. Contract Sales & Medical Solutions (CSMS) revenue was $209 million, up 16.1 percent reported. Management cited R&DS bookings growth of 13 percent year-over-year and RFP growth of 20 percent. Balance sheet leverage stood at a Net Leverage Ratio of 3.52x trailing twelve-month Adjusted EBITDA, with net debt of $13,143 million. For full-year 2025, IQVIA reaffirmed the midpoint of its guidance and narrowed ranges: revenue of $16,150 million to $16,250 million, Adjusted EBITDA of $3,775 million to $3,800 million, and Adjusted Diluted EPS of $11.85 to $11.95. The revenue guidance includes approximately $100 million of COVID-related revenue step-down, entirely in R&DS.

Oct 28, 2025 8-K

IQVIA Holdings 8-K Report, Executive Changes (Sep 2, 2025)

IQVIA Holdings Inc. (IQV) announced a planned leadership transition in its finance organization. Michael J. Fedock, currently Senior Vice President, Financial Planning and Analysis, will succeed Ronald E. Bruehlman as Executive Vice President and Chief Financial Officer effective February 28, 2026. The change is part of the Company's previously announced CFO succession plan. Fedock, age 50, joined the Company in 2016 and has more than 25 years of healthcare industry experience. He previously served as CFO of the Research & Development Solutions Business Unit (July 2019 to April 2021) and as CFO of IQVIA Laboratories (May 2016 to July 2019). In connection with his promotion, his annual base salary will increase to $750,000, with an annual cash incentive target of 100% of base salary and eligibility for annual Long Term Incentive cycles under the Company's 2017 Incentive and Stock Award Plan. Bruehlman will retire as CFO effective February 28, 2026, and transition to Senior Advisor to CEO Ari Bousbib. The filing describes the move as ensuring continuity and a seamless transition. The announcement was made through a press release dated September 2, 2025, furnished as Exhibit 99.1.

Sep 2, 2025 8-K

IQVIA Holdings 8-K Report, Financial Results (Jul 22, 2025)

IQVIA Holdings Inc. filed this Form 8-K under Item 2.02 (Results of Operations and Financial Condition) to furnish its press release reporting second-quarter 2025 results for the quarter ended June 30, 2025. Revenue was $4,017 million, up 5.3 percent on a reported basis and 3.6 percent at constant currency. GAAP Net Income was $266 million and GAAP Diluted EPS was $1.54, while Adjusted EBITDA was $910 million and Adjusted Diluted EPS was $2.81. TAS revenue of $1,628 million grew 8.9 percent reported, R&DS revenue of $2,201 million grew 2.5 percent reported, and R&DS contracted backlog reached $32.1 billion, up 5.1 percent year-over-year. R&DS quarterly bookings were $2.5 billion, a book-to-bill ratio of 1.12x. The company updated full-year 2025 guidance to revenue of $16,100 million to $16,300 million, Adjusted EBITDA of $3,750 million to $3,825 million, and Adjusted Diluted EPS of $11.75 to $12.05. The guidance assumes approximately $100 million of COVID-related revenue step-down, entirely in R&DS. As of June 30, 2025, cash and cash equivalents were $2,039 million, debt was $15,490 million, and net debt was $13,451 million, a Net Leverage Ratio of 3.61x trailing twelve-month Adjusted EBITDA. Second-quarter Operating Cash Flow was $443 million and Free Cash Flow was $292 million. During the quarter, IQVIA repurchased $607 million of common stock, bringing first-half repurchases to $1,032 million, with $1,981 million of authorization remaining as of June 30, 2025. The filing states that the information is furnished and not deemed filed under Section 18 of the Exchange Act.

Jul 22, 2025 10-Q

IQVIA Holdings Quarterly Report for Q2 Ended Jun 30, 2025

IQVIA Holdings Inc. reported second-quarter 2025 revenues of $4,017 million, up $203 million, or 5.3%, from $3,814 million a year earlier, with constant currency revenue growth of approximately $139 million, or 3.6%. Net income fell to $266 million from $363 million, and diluted EPS was $1.54 versus $1.97. Income from operations declined to $506 million from $520 million, as higher cost of revenues (up $206 million, to 67.1% of revenues from 65.2%) and higher interest expense ($182 million versus $163 million) outpaced revenue growth. For the six months, revenues rose 3.9% to $7,846 million, while net income dropped to $515 million from $651 million and diluted EPS was $2.94 versus $3.53. Balance sheet and capital activity were significant in the period. Total debt principal rose to $15,573 million from $14,045 million at December 31, 2024, driven by the June 2025 issuance of $2,000 million of 6.250% senior notes due 2032 and a March 2025 incremental Term B-5 loan of $1,985 million. Cash and equivalents increased to $2,039 million from $1,702 million. The company repurchased 6.4 million shares for $1,032 million in the first half, leaving $1,981 million of remaining authorization under its Repurchase Program. Goodwill increased to $15,611 million, largely from foreign currency effects and business combinations. Operationally, Research & Development Solutions remained the largest segment at $2,201 million of second-quarter revenue, though its segment profit fell to $451 million from $493 million. Technology & Analytics Solutions grew revenue 8.9% in the quarter to $1,628 million, with segment profit up 7.8% to $389 million. Backlog for Research & Development Solutions rose to $32.1 billion from $31.1 billion at December 31, 2024. Management stated that disclosure controls were effective and that no material changes were made to its risk factors.

Jul 22, 2025 8-K

IQVIA Holdings 8-K Report, Material Agreement (Jun 4, 2025)

IQVIA Holdings Inc. (IQV) disclosed in this Form 8-K that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), completed the issuance and sale of $2.0 billion in gross proceeds of 6.250% senior notes due 2032 on June 4, 2025. The notes are unsecured obligations of the Issuer, mature on June 1, 2032, and pay interest semi-annually on June 1 and December 1, beginning December 1, 2025. The notes were issued under an Indenture dated June 4, 2025, with U.S. Bank Trust Company, National Association, as trustee, and certain Issuer subsidiaries as guarantors. Net proceeds will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses of the offering, with any excess used for general corporate purposes. The filing states that the Issuer may redeem the notes before maturity subject to a customary make-whole premium at any time before June 1, 2028 (subject to a customary "equity claw" right), and thereafter at a redemption premium declining from 3.125% to 0.000%. The filing is a debt financing event that refinances revolving credit borrowings with fixed-rate longer-dated notes. Item 1.01 and Item 2.03 describe the transaction, and Item 9.01 lists the Indenture (Exhibit 4.1) and the cover page interactive data file (Exhibit 104).

Jun 4, 2025 8-K

IQVIA Holdings 8-K Report, Corporate Update (Jun 2, 2025)

IQVIA Holdings Inc. (IQV) announced on June 2, 2025 that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise $2,000,000,000 in gross proceeds through an offering of senior notes due 2032. The Issuer entered into a purchase agreement on the same day for the sale of $2.00 billion in aggregate principal amount of these notes, which bear interest at 6.250% per annum. Closing is expected on or about June 4, 2025, subject to customary closing conditions. The company stated that net proceeds will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the offering, with any excess used for other general corporate purposes. For investors, the transaction is primarily a refinancing: it replaces revolving credit borrowings with fixed-rate senior notes maturing June 1, 2032, and the filing does not state any change in total debt beyond the stated use of proceeds. The notes are being offered under Rule 144A to qualified institutional buyers in the United States and under Regulation S outside the United States, and have not been registered under the Securities Act. The filing's forward-looking statements caution that the offering may fail to close and that market conditions could cause results to differ materially.

Jun 2, 2025 8-K

IQVIA Holdings 8-K Report, Financial Results (May 6, 2025)

IQVIA Holdings Inc. reported first-quarter 2025 results on May 6, 2025, with revenue of $3,829 million, up 2.5 percent on a reported basis and 3.5 percent at constant currency. GAAP net income was $249 million and GAAP diluted earnings per share were $1.40, while Adjusted EBITDA was $883 million, up 2.4 percent year-over-year, and Adjusted Diluted Earnings per Share were $2.70, up 6.3 percent. Technology & Analytics Solutions (TAS) was the standout segment, with revenue of $1,546 million growing 7.6 percent at constant currency. Management attributed softness in clinical trial business to delayed customer decision-making on new programs amid macroeconomic and industry uncertainty, though R&DS forward-looking indicators such as qualified pipeline, RFP flow and backlog continued to grow. R&DS revenue of $2,102 million rose 0.3 percent on a reported basis, and contracted backlog reached $31.5 billion, up 4.8 percent year-over-year. First-quarter R&DS net new bookings were $2.1 billion, for a trailing-twelve-month book-to-bill ratio of 1.14x. Contract Sales & Medical Solutions revenue declined 4.2 percent on a reported basis to $181 million. The company raised full-year 2025 revenue guidance to between $16,000 million and $16,400 million, reflecting favorable foreign currency movements, and reaffirmed Adjusted EBITDA guidance of $3,765 million to $3,885 million and Adjusted Diluted EPS guidance of $11.70 to $12.10. Balance sheet metrics show debt of $14,330 million, net debt of $12,590 million and a Net Leverage Ratio of 3.40x. The company repurchased $425 million of common stock during the quarter and had $2,588 million of authorization remaining.

May 6, 2025 10-Q

IQVIA Holdings Quarterly Report for Q1 Ended Mar 31, 2025

IQVIA Holdings Inc. (IQV) reported first-quarter 2025 revenues of $3.83 billion, up from $3.74 billion a year earlier, with constant currency revenue growth of approximately $129 million, or 3.5%. Net income fell to $249 million from $288 million, and diluted earnings per share were $1.40 versus $1.56. Income from operations declined to $496 million from $506 million, driven mainly by higher restructuring costs of $29 million versus $15 million, and cost of revenues rose to 66.1% of revenues from 65.4%. Segment results were mixed. Technology & Analytics Solutions revenues rose 6.4% to $1.55 billion with segment profit up 7.5% to $360 million, while Research & Development Solutions revenues were essentially flat at $2.10 billion and segment profit fell 4.0% to $460 million. Contract Sales & Medical Solutions revenues declined 4.2% to $181 million. Total backlog for Research & Development Solutions rose to $31.5 billion from $31.1 billion, with approximately $7.9 billion expected to convert to revenue in the next twelve months. On the balance sheet, total debt principal rose to $14.39 billion from $14.05 billion, and cash rose to $1.74 billion. In March 2025 the company refinanced term loans with a new $1.985 billion Term B-5 dollar facility and recognized a $4 million loss on extinguishment of debt. The company repurchased 2.3 million shares for $425 million under its repurchase program, leaving $2.59 billion of remaining authorization after the Board increased the program by $2.0 billion in February 2025. Operating cash flow increased to $568 million from $522 million.

May 6, 2025 8-K

IQVIA Holdings 8-K Report, Bylaw Amendment (Apr 24, 2025)

On April 24, 2025, IQVIA Holdings Inc. held its 2025 Annual Meeting of Stockholders, where shareholders approved an amendment to the Amended and Restated Certificate of Incorporation. The amendment provides for exculpation from liability for certain officers to the fullest extent permitted by Delaware law and removes obsolete provisions tied to the company's previous classified board structure. The amended charter became effective upon filing with the Delaware Secretary of State on April 24, 2025. At the meeting, all nine director nominees were elected to one-year terms by majority vote. Stockholders also approved, on an advisory basis, the 2024 compensation of the named executive officers, though with a notably larger Against count (26,212,786) than For count (125,637,769) among the votes cast. PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2025, with 145,558,841 votes for and 14,744,090 against. A non-binding stockholder proposal concerning special stockholder meetings did not pass, receiving 66,155,724 votes for and 86,013,439 against. The record date was February 24, 2025, with 176,315,036 shares of common stock outstanding and entitled to vote on all matters.

Apr 24, 2025 8-K

IQVIA Holdings 8-K Report, Material Agreement (Mar 10, 2025)

IQVIA Holdings Inc. (IQV) disclosed in this Form 8-K filed March 10, 2025 that it entered into Amendment No. 4 to its Fifth Amended and Restated Credit Agreement on that date. The amendment creates a new class of term B dollar loans used to refinance its Term B-4 Dollar Loans, lowering the interest rate on those borrowings from SOFR plus an applicable margin of 2.00% per annum to SOFR plus 1.75% per annum. The new loans also fund the repayment in full of its Term B-2 Euro Loans. The transaction is a debt refinancing rather than new borrowing for growth or acquisitions. The filing describes the change as a reduction in the margin on the refinanced dollar term loans, along with the retirement of the Euro-denominated term loans. The filing does not include financial results, guidance, or other operating information. The amendment is filed as Exhibit 10.1, which names IQVIA Inc., IQVIA Holdings Inc., IQVIA RDS Inc., other guarantors, Bank of America, N.A. as administrative and collateral agent, and the lending parties. Item 2.03 incorporates the Item 1.01 disclosure by reference.

Mar 10, 2025 10-K

IQVIA Holdings Annual Report, Year Ended Dec 31, 2024

IQVIA Holdings Inc. reported 2024 revenues of $15.41 billion, up $421 million, or 2.8%, from $14.98 billion in 2023, with constant currency revenue growth of approximately $510 million, or 3.4%. Income from operations rose to $2,202 million from $1,977 million, and net income increased to $1,373 million from $1,358 million. Diluted EPS was $7.49, compared with $7.29 in 2023. Cash provided by operating activities increased to $2,716 million from $2,149 million, which the filing attributes primarily to higher cash from accounts receivable and unbilled services. The company ended the year with its highest-ever total remaining performance obligations of approximately $33.5 billion. By segment, Technology & Analytics Solutions revenue grew 5.1% to $6,160 million and Research & Development Solutions grew 1.6% to $8,527 million, while Contract Sales & Medical Solutions declined 1.2% to $718 million. Research & Development Solutions contracted backlog rose to $31.1 billion from $29.7 billion, with approximately $7.9 billion expected to convert to revenue in the next 12 months. Management noted challenges in Research & Development Solutions in the latter half of 2024 that it expects may persist into 2025, which it considers more short-term in nature. Balance sheet and capital allocation: cash and cash equivalents were $1,702 million at year-end, against total indebtedness of $14,045 million and $825 million drawn under a $2,000 million revolving credit facility. The company repurchased 6.4 million shares for $1,350 million in 2024, and on February 5, 2025 the Board added $2,000 million to the repurchase authorization, bringing the total authorized to $13,725 million. Remaining authorization as of December 31, 2024 was $1,013 million. The company paid no dividends in 2024 or 2023.

Feb 13, 2025 8-K

IQVIA Holdings 8-K Report, Financial Results (Feb 6, 2025)

IQVIA Holdings Inc. filed this Form 8-K under Item 2.02 to furnish a press release reporting fourth-quarter and full-year 2024 results. For the fourth quarter, revenue was $3,958 million, up 2.3 percent on a reported basis and 3.0 percent at constant currency. GAAP net income was $437 million and GAAP diluted EPS was $2.42, while Adjusted Diluted EPS was $3.12 and Adjusted EBITDA was $996 million. For the full year, revenue was $15,405 million, GAAP net income was $1,373 million, and Adjusted Diluted EPS was $11.13, up 9.1 percent. Operating cash flow reached $2,716 million and free cash flow reached $2,114 million, up 26 percent and 41 percent year-over-year, respectively. The R&D Solutions segment booked over $2.5 billion in the quarter, a book-to-bill ratio of 1.20x, and ended the year with contracted backlog of $31.1 billion. The Technology & Analytics Solutions segment grew 9.5 percent at constant currency in the quarter and reached $6,160 million for the full year. Net debt was $12,281 million, and the Net Leverage Ratio was 3.33x trailing twelve-month Adjusted EBITDA. The company repurchased $1,350 million of stock in 2024 and, on February 5, 2025, increased its repurchase authorization by $2,000 million to a total of $3,013 million. Management reaffirmed its 2025 outlook, including revenue guidance of $15,725 million to $16,125 million, Adjusted EBITDA of $3,765 million to $3,885 million, and Adjusted Diluted EPS of $11.70 to $12.10, with constant-currency ex-COVID revenue growth of 4 to 7 percent.

Feb 6, 2025 10-Q

IQVIA Holdings Quarterly Report for Q3 Ended Sep 30, 2024

IQVIA Holdings Inc. reported third-quarter 2024 revenues of $3,896 million, up $160 million, or 4.3%, from $3,736 million a year earlier. Net income was $285 million versus $303 million, and diluted EPS was $1.55 compared with $1.63. For the first nine months, revenues were $11,447 million (up 3.0%) and net income was $936 million, with diluted EPS of $5.08 versus $4.76. Research & Development Solutions contracted backlog rose to $31.1 billion from $29.7 billion at December 31, 2023, and total remaining performance obligations were approximately $33.3 billion. Cash flow strengthened. Net cash provided by operating activities was $1,831 million for the nine months, up from $1,402 million, and cash and cash equivalents rose to $1,572 million. The company repurchased $200 million of stock in the nine months, leaving $2,163 million of remaining authorization under its Repurchase Program. Total indebtedness was $13,578 million, with $1,995 million of additional revolver availability. At the segment level, Technology & Analytics Solutions segment profit rose 14.1% in the quarter, while Research & Development Solutions segment profit was $498 million versus $495 million. Contract Sales & Medical Solutions revenues declined 1.6% in the quarter. The company stated that its legal matters in Korea were resolved in its favor when the Supreme Court dismissed appeals on July 11, 2024, and that the Veeva litigation trial is scheduled for early 2025.

Oct 31, 2024 8-K

IQVIA Holdings 8-K Report, Financial Results (Oct 31, 2024)

IQVIA Holdings Inc. filed this Form 8-K on October 31, 2024 to furnish its press release reporting third-quarter 2024 results, along with an update to full-year 2024 guidance and the announcement of an Investor Day on December 10, 2024. Third-quarter revenue was $3,896 million, up 4.3 percent on a reported basis, with GAAP Net Income of $285 million, Adjusted EBITDA of $939 million, and GAAP Diluted EPS of $1.55 versus Adjusted Diluted EPS of $2.84. Technology & Analytics Solutions (TAS) revenue of $1,554 million grew 8.6 percent reported, while R&D Solutions (R&DS) revenue of $2,162 million rose 1.9 percent reported. R&DS contracted backlog reached $31.1 billion, up 8.0 percent year-over-year, and the third-quarter book-to-bill ratio was 1.06x, which includes a large program cancellation due to drug futility. Management lowered full-year 2024 guidance to revenue of $15,350 million to $15,400 million, Adjusted EBITDA of $3,675 million to $3,700 million, and Adjusted Diluted EPS of $11.10 to $11.20. The company attributed the update to delays in two fast-burning mega trials caused by client-related short-term logistical challenges, which are now expected to ramp in the second half of 2025. Operating cash flow for the first nine months was $1,831 million and free cash flow was $1,393 million, while net debt stood at $11,940 million, a Net Leverage Ratio of 3.27x trailing twelve-month Adjusted EBITDA. The company repurchased $200 million of common stock in the third quarter and had $2,163 million of authorization remaining as of September 30, 2024. Chairman and CEO Ari Bousbib stated that margins expanded, free cash flow was strong, and TAS growth accelerated, while R&DS fundamentals remain solid based on RFP flow, qualified pipeline growth, backlog growth, and next-twelve-month revenue from backlog.

Oct 31, 2024 8-K

IQVIA Holdings 8-K Report, Financial Results (Jul 22, 2024)

IQVIA Holdings Inc. (IQV) furnished an 8-K on July 22, 2024 under Item 2.02 (Results of Operations and Financial Condition), attaching a press release (Exhibit 99.1) reporting results for the second quarter ended June 30, 2024. Second-quarter revenue was $3,814 million, up 2.3 percent on a reported basis and 3.5 percent at constant currency. GAAP net income was $363 million, or $1.97 per diluted share, and Adjusted EBITDA was $887 million. Adjusted diluted EPS was $2.64. Management said the quarter came in at the high end of guidance, driven mainly by better-than-expected Technology & Analytics Solutions (TAS) performance. R&D Solutions (R&DS) showed continued strength: quarterly bookings were $2.7 billion, a book-to-bill ratio of 1.27x, and contracted backlog reached $30.6 billion, up 7.7 percent reported and 8.1 percent at constant currency year-over-year. The company expects approximately $7.8 billion of that backlog to convert to revenue in the next twelve months. Contract Sales & Medical Solutions revenue of $172 million declined 2.3 percent on a reported basis. Balance sheet metrics show total debt of $13,258 million and net debt of $11,713 million as of June 30, 2024, with a Net Leverage Ratio of 3.25x trailing twelve-month Adjusted EBITDA. Second-quarter operating cash flow was $588 million and free cash flow was $445 million. The company updated full-year 2024 guidance: revenue of $15,425 million to $15,525 million, Adjusted EBITDA of $3,705 million to $3,765 million, and Adjusted Diluted EPS of $11.10 to $11.30, assuming foreign exchange rates as of July 18, 2024.

Jul 22, 2024 10-Q

IQVIA Holdings Quarterly Report for Q2 Ended Jun 30, 2024

IQVIA Holdings Inc. reported second-quarter 2024 revenues of $3.81 billion, up $86 million, or 2.3%, from $3.73 billion a year earlier, with constant currency revenue growth of approximately $130 million, or 3.5%. Net income rose to $363 million from $297 million, and diluted earnings per share increased to $1.97 from $1.59. For the first six months, revenues were $7.55 billion (up 2.3%) and net income was $651 million versus $586 million. Income from operations for the quarter was $520 million, roughly flat against $524 million, as cost of revenues and SG&A growth outpaced revenue growth; restructuring costs rose to $28 million from $20 million. Other income, net of $67 million in the quarter was driven mainly by revaluations of contingent consideration arrangements. Cash flow strengthened, with net cash provided by operating activities of $1.11 billion for the six months versus $819 million a year earlier. Cash and cash equivalents were $1.55 billion at June 30, 2024. Total indebtedness was $13.33 billion, and the company had $1.995 billion of additional available borrowing capacity under its revolving credit facility. The company did not repurchase any shares under its Repurchase Program during the six months, leaving $2.36 billion of remaining authorization. The filing also reports that on July 11, 2024, the Supreme Court of South Korea dismissed appeals in the IMS Korea privacy and criminal matters, making those decisions final in the company's favor. The Veeva litigation remains pending, with trial scheduled for early 2025 and Veeva claiming damages in excess of $200 million on its counterclaims.

Jul 22, 2024 8-K

IQVIA Holdings 8-K Report, Executive Changes (May 10, 2024)

IQVIA Holdings Inc. (IQV) filed a Current Report on Form 8-K dated May 10, 2024, reporting an event from May 6, 2024. Under Item 5.02 (Departure of Directors or Certain Officers; Compensatory Arrangements of Certain Officers), the Company announced that Kevin C. Knightly, President, Corporate Strategy and Enterprise Networks, will transition from his current role effective May 15, 2024. Following the transition, Mr. Knightly will become a senior advisor to the Chief Executive Officer. The filing states that he will receive compensation commensurate with this new role, but it does not disclose the amount or terms of that compensation. The filing is a limited leadership notice. It contains no financial results, guidance, or other financial metrics, so the change is primarily a management and governance development for investors to note.

May 10, 2024 10-Q

IQVIA Holdings Quarterly Report for Q1 Ended Mar 31, 2024

IQVIA Holdings Inc. reported first-quarter 2024 revenues of $3,737 million, up $85 million, or 2.3%, from $3,652 million in the first quarter of 2023. Income from operations rose to $506 million from $471 million, but net income was essentially flat at $288 million versus $289 million, as interest expense increased to $166 million from $141 million and other expense (income), net swung to an $11 million expense from $26 million of income. Diluted earnings per share were $1.56, up from $1.53, helped by a lower diluted share count of 184.3 million versus 188.6 million. Management attributed the revenue increase to constant currency growth of approximately $105 million, or 2.9%, led by Research & Development Solutions, which grew $69 million, or 3.4%, and saw contracted backlog rise to $30.1 billion from $29.7 billion. Cash flow from operations improved to $522 million from $417 million. Cash and cash equivalents ended the quarter at $1,444 million, and total indebtedness was $13,611 million, with $1,895 million of additional revolving credit availability. The company repurchased no shares under its equity repurchase program during the quarter and had $2,363 million of remaining authorization. Results were also affected by a lower effective income tax rate of 14.4%, compared with 19.6% a year earlier. The filing also describes ongoing legal matters, including the Veeva Systems litigation, in which trial has been scheduled for early 2025, and a Korean privacy-related lawsuit that is on appeal. Management believes that pending proceedings are not expected to have a material adverse effect on results, cash flows or financial position.

May 2, 2024 8-K

IQVIA Holdings 8-K Report, Financial Results (May 2, 2024)

IQVIA Holdings Inc. reported first-quarter 2024 results in a press release dated May 2, 2024, furnished as Exhibit 99.1 under Item 2.02. Revenue was $3,737 million, up 2.3 percent on a reported basis and 2.9 percent at constant currency, compared with the first quarter of 2023. GAAP net income was $288 million and GAAP diluted EPS was $1.56, while Adjusted Net Income was $468 million, Adjusted Diluted EPS was $2.54, and Adjusted EBITDA was $862 million, up 1.3 percent year-over-year. By segment, Technology & Analytics Solutions revenue was $1,453 million, up 0.6 percent reported, and Research & Development Solutions revenue was $2,095 million, up 3.4 percent reported. Contract Sales & Medical Solutions revenue was $189 million, up 3.8 percent reported. R&DS contracted backlog reached $30.1 billion, up 7.9 percent year-over-year, and the first-quarter book-to-bill ratio was 1.23x, including the cancellation of a large central nervous system program. The company expects approximately $7.7 billion of backlog to convert to revenue in the next twelve months. The company reaffirmed full-year 2024 guidance: revenue of $15,325 million to $15,575 million on a reported basis (growth of 2.3 to 3.9 percent), Adjusted EBITDA of $3,700 million to $3,800 million, and Adjusted Diluted EPS of $10.95 to $11.25. Net debt was $12,092 million at March 31, 2024, with a Net Leverage Ratio of 3.38x trailing twelve-month Adjusted EBITDA, and first-quarter Free Cash Flow was $377 million.

May 2, 2024 8-K

IQVIA Holdings 8-K Report, Shareholder Vote Results (Apr 17, 2024)

IQVIA Holdings Inc. filed this Form 8-K under Item 5.07 to report the voting results of its 2024 Annual Meeting of Stockholders, held April 16, 2024. As of the February 20, 2024 record date, 182,013,590 shares of common stock were outstanding and entitled to vote. Stockholders re-elected all six board nominees (Ari Bousbib, Carol J. Burt, Colleen A. Goggins, John M. Leonard, MD, Todd B. Sisitsky and Sheila A. Stamps) to one-year terms. Sisitsky drew the weakest support, with 129,897,117 votes for and 30,538,472 against, while the other nominees received far more votes for than against. Stockholders approved, on an advisory basis, the 2023 compensation of the named executive officers, with 134,057,263 votes for and 26,075,678 against. A non-binding stockholder proposal concerning political spending was not approved, receiving 21,082,315 votes for and 137,953,664 against. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2024, with 152,245,315 votes for and 14,801,559 against. For investors, the filing shows broad support for the board slate, the executive pay program and the auditor, with the main dissent concentrated in the director vote for Sisitsky and the stockholder proposal on political spending. The 8-K reports only the meeting outcomes and does not discuss financial performance.

Apr 17, 2024 10-K

IQVIA Holdings Annual Report, Year Ended Dec 31, 2023

IQVIA Holdings Inc. reported 2023 revenues of $14.98 billion, up $574 million, or 4.0%, from $14.41 billion in 2022, with income from operations of $1.98 billion and net income of $1.36 billion, or $7.29 diluted EPS, compared with $1.09 billion and $5.72 in 2022. Research & Development Solutions drove growth, with revenues of $8.40 billion (up 6.0%) and segment profit of $1.92 billion, while Technology & Analytics Solutions revenues rose 2.0% to $5.86 billion and Contract Sales & Medical Solutions declined 2.2% to $727 million. Management highlighted record remaining performance obligations of approximately $31.7 billion and R&D contracted backlog of $29.7 billion, though it noted a more cautious spending environment for Technology & Analytics Solutions clients. The company's effective tax rate fell to 6.9% from 19.1%, largely due to a $125 million benefit from an internal legal entity restructuring, which contributed meaningfully to the earnings increase. Operating cash flow declined to $2.15 billion from $2.26 billion. Total debt was $13.75 billion at year-end, and the company ended the year with $1.38 billion in cash, after issuing $1.5 billion of incremental Term B-4 loans and $1.25 billion of 6.250% senior secured notes due 2029 in November 2023, along with $750 million of 5.700% senior secured notes due 2028 and $500 million of 6.500% senior notes due 2030 in May 2023. IQVIA repurchased $992 million of common stock in 2023 and had $2.36 billion remaining under its repurchase authorization. Risk factors highlighted client contract cancellations and delays, data-supplier dependence, data privacy regulation, and the pending Veeva litigation, in which the company is the plaintiff and Veeva has counterclaimed for damages in excess of $200 million.

Feb 15, 2024 8-K

IQVIA Holdings 8-K Report, Financial Results (Feb 14, 2024)

IQVIA Holdings Inc. furnished an 8-K on February 14, 2024 (Item 2.02) attaching a press release reporting fourth-quarter and full-year 2023 results and issuing full-year 2024 guidance. For Q4 2023, revenue was $3,868 million (up 3.5 percent reported), GAAP net income was $469 million, and Adjusted EBITDA was $966 million. For full-year 2023, revenue was $14,984 million (up 4.0 percent reported), GAAP net income was $1,358 million, GAAP diluted EPS was $7.29, Adjusted Diluted EPS was $10.20 (up 0.4 percent), and Adjusted EBITDA was $3,569 million (up 6.7 percent). R&DS contracted backlog reached $29.7 billion, growing 9.2 percent year-over-year, and the fourth-quarter book-to-bill ratio was 1.31x. The company ended 2023 with cash of $1,376 million, debt of $13,673 million and net debt of $12,297 million, a Net Leverage Ratio of 3.45x. Operating cash flow for the full year was $2,149 million and free cash flow was $1,500 million. The company refinanced approximately $2.75 billion of near-term maturities in the fourth quarter, extending maturities to 2029 and 2031 at an average fixed rate below 4.9 percent after swaps, and over 80 percent of its debt is now fixed-rate. Share repurchases totaled $992 million for the year, with $2,363 million of authorization remaining. For 2024, IQVIA guided to revenue of $15,400 million to $15,650 million, Adjusted EBITDA of $3,700 million to $3,800 million, and Adjusted Diluted EPS of $10.95 to $11.25. The revenue outlook assumes roughly $300 million of COVID-related revenue step-down, about 50 basis points of foreign exchange headwind, and about 100 basis points of contribution from acquisitions. Management described the 2023 results as solid in a challenging macro environment, citing strong clinical demand and a 1.31 book-to-bill ratio for the quarter.

Feb 14, 2024 8-K

IQVIA Holdings 8-K Report, Material Agreement (Nov 28, 2023)

IQVIA Holdings Inc. (IQV) disclosed on November 28, 2023 that its wholly owned subsidiary, IQVIA Inc. (the Issuer or Borrower), completed the issuance and sale of $1.25 billion in gross proceeds of 6.250% senior secured notes due 2029. The Notes are secured obligations of the Issuer, mature on February 1, 2029, pay interest semi-annually on February 1 and August 1 beginning February 1, 2024, and are issued under an Indenture with U.S. Bank Trust Company, National Association as trustee and collateral agent, with the Company and certain subsidiaries as guarantors. The Issuer may redeem the Notes before January 1, 2029 subject to a customary make-whole premium, and on or after that date at 100% of principal plus accrued and unpaid interest. Concurrently, the Company entered into Amendment No. 3 to its Fifth Amended and Restated Credit Agreement, under which it borrowed $1.5 billion in incremental Term B-4 Dollar Loans. The net proceeds of the Notes and the Term B-4 loans will be used to repay the Euro-denominated term B loan due March 2024, the U.S. dollar term B loans due January 2025 and June 2025, and to pay related fees and expenses. Under Item 8.01, the filing states that the Company entered into two cross-currency swap agreements (November 15 and November 17, 2023) that effectively convert the Notes and Term B-4 Dollar Loans into euro-denominated borrowings at prevailing euro rates, with effective net borrowing rates of 4.8555% for the Notes and 4.9015% for the Term B-4 Dollar Loans.

Nov 28, 2023 8-K

IQVIA Holdings 8-K Report, Corporate Update (Nov 15, 2023)

On November 14, 2023, IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., intended to raise $500 million through senior secured notes due 2029 and to refinance part of its existing debt. The same day, the Issuer entered into a purchase agreement for $1.25 billion of senior secured notes due 2029 bearing interest at 6.250% per annum. The closing is expected on or about November 28, 2023, subject to customary closing conditions. On November 15, 2023, the company announced the pricing of the offering, which was upsized due to strong demand to $1.25 billion in aggregate principal amount, including an additional $750 million. Concurrently, the Issuer intends to amend its senior secured credit facilities to add a new term B loan due 2031 of approximately $1.25 billion. Proceeds from the notes and the new term loan are expected to repay certain outstanding term loans due in 2024 and 2025, and to pay related fees and expenses. In connection with the pricing, the company entered into a cross-currency swap agreement to convert $1.25 billion of the notes into a euro-denominated borrowing, with an effective net borrowing rate of approximately 4.8555%. The company also intends to enter into additional cross-currency swaps to hedge dollar-denominated debt created by the new term loan, though there is no assurance it will do so. The filing states that the Credit Agreement Amendment and the new term loan are not conditioned on the notes offering, and the notes offering is not conditioned on them.

Nov 15, 2023 10-Q

IQVIA Holdings Quarterly Report for Q3 Ended Sep 30, 2023

IQVIA Holdings Inc. reported third-quarter 2023 revenues of $3.74 billion, up 4.9% from $3.56 billion a year earlier, with net income of $303 million versus $283 million and diluted EPS of $1.63 versus $1.49. For the first nine months, revenues were $11.12 billion (up 4.2%) and net income was $889 million versus $864 million, with diluted EPS of $4.76 versus $4.52. Constant currency revenue growth was approximately 4.1% in the quarter and 4.8% for the nine months, and Research & Development Solutions was the main driver, with segment revenue up 7.2% in the quarter. Cash flow from operations declined to $1.40 billion for the nine months from $1.70 billion, mainly due to lower cash from other operating assets and liabilities and unearned income. Interest expense rose to $491 million from $288 million, reflecting higher base rates and increased net debt. Total debt principal was $13.69 billion at September 30, 2023, against $1.745 billion of available revolver capacity. In May 2023 the company issued $750 million of 5.700% senior secured notes due 2028 and $500 million of 6.500% senior notes due 2030, using the proceeds to repay revolver borrowings. The company repurchased $763 million of stock in the first nine months, and its Board raised the Repurchase Program authorization by $2.0 billion on July 31, 2023, to $11.725 billion total, with $2.592 billion remaining at quarter end. The filing also notes that the company expects to reverse a valuation allowance on certain foreign tax credits in the near term, which could create a material discrete tax benefit. Pending litigation includes the Veeva Systems matter, in which Veeva claims damages in excess of $200 million on its counterclaims, while the company says those counterclaims are without merit.

Nov 1, 2023 8-K

IQVIA Holdings 8-K Report, Financial Results (Nov 1, 2023)

IQVIA Holdings Inc. (NYSE: IQV) reported third-quarter 2023 results on November 1, 2023, via a press release furnished as Exhibit 99.1 under Item 2.02. Revenue was $3,736 million, up 4.9 percent on a reported basis and 4.1 percent at constant currency. GAAP net income was $303 million, GAAP diluted EPS was $1.63, Adjusted Net Income was $462 million, and Adjusted Diluted EPS was $2.49. Adjusted EBITDA was $888 million, up 9.1 percent year-over-year. R&DS, the largest segment, posted revenue of $2,122 million, up 7.2 percent on a reported basis, a quarterly book-to-bill ratio of 1.24x, and contracted backlog of $28.8 billion, up 11.7 percent year-over-year. TAS revenue of $1,431 million grew 2.2 percent, while CSMS revenue was flat at $183 million. The company lowered its full-year 2023 revenue guidance to $14,885 million to $14,920 million, citing slower growth in TAS and the stronger U.S. dollar. Adjusted EBITDA guidance was narrowed to $3,560 million to $3,570 million, and Adjusted Diluted EPS guidance was set at $10.16 to $10.23. For the fourth quarter, the company expects revenue of $3,769 million to $3,804 million and Adjusted Diluted EPS of $2.79 to $2.86. Balance sheet metrics were mixed. Cash and equivalents were $1,224 million against debt of $13,631 million, giving net debt of $12,407 million and a Net Leverage Ratio of 3.52x. Nine-month operating cash flow was $1,402 million and free cash flow was $932 million. The company repurchased $763 million of stock year-to-date and had $2,592 million of authorization remaining.

Nov 1, 2023 8-K

IQVIA Holdings 8-K Report, Executive Changes (Sep 26, 2023)

IQVIA Holdings Inc. (IQV) filed this Form 8-K on September 26, 2023 to report a leadership change in its Research & Development Solutions (R&DS) business unit. The company appointed Richard Staub III as President of R&DS, effective September 25, 2023. Staub previously led the R&DS business unit from 2016 to 2022 and, most recently, served as a senior advisor to the Company's Chairman and CEO, where he had responsibility for key customer relationships and guided the business's strategic direction. He brings thirty-four years of relevant industry experience. The filing also discloses the departure of Costa Panagos, who had been President of R&DS. Panagos informed the Company on September 24, 2023 of his intention to leave, and his last day was September 25, 2023. Per his Confidentiality and Restrictive Covenants Agreement, he is subject to noncompetition and nonsolicitation covenants for 12 months following the termination of his employment. The press release announcing both changes, dated September 25, 2023, is furnished as Exhibit 99.1 under Item 7.01. For investors, the key takeaway is a return of an experienced executive to lead the R&DS segment, with the press release describing his prior tenure as including record backlog, industry-leading book-to-bill ratios and significantly increased R&DS revenues. The filing itself does not provide financial results or guidance tied to this change.

Sep 26, 2023 10-Q

IQVIA Holdings Quarterly Report for Q2 Ended Jun 30, 2023

IQVIA Holdings Inc. reported second-quarter 2023 revenues of $3.73 billion, up $187 million, or 5.3%, from $3.54 billion a year earlier, with constant currency revenue growth of approximately $196 million, or 5.5%. Income from operations rose to $524 million from $453 million, and net income increased to $297 million from $256 million. Diluted EPS was $1.59 versus $1.34. For the six months, revenues were $7.38 billion, up 3.8%, and net income was $586 million compared with $581 million. Interest expense more than doubled in the quarter to $169 million from $94 million, reflecting higher base rate costs on floating rate debt and higher net debt. Total indebtedness was $13.84 billion as of June 30, 2023, and cash and cash equivalents were $1.38 billion. In May 2023 the Issuer completed the sale of $750 million of 5.700% senior secured notes due 2028 and $500 million of 6.500% senior notes due 2030, with proceeds used to repay revolving credit borrowings. The company increased its revolving credit facility capacity by $500 million to $2.00 billion in April 2023. Cash used for share repurchases in the first six months was $619 million, and on July 31, 2023 the Board increased the repurchase authorization by $2.00 billion to a total of $11.73 billion, leaving $2.74 billion available. The filing also describes Research & Development Solutions backlog of $28.4 billion as of June 30, 2023, up from $27.2 billion at year-end 2022, and total remaining performance obligations of approximately $31.0 billion. Ongoing litigation includes the Veeva Systems matter, where Veeva is appealing a May 2021 court order, and Korean privacy proceedings, which the company says it is vigorously defending.

Aug 1, 2023 8-K

IQVIA Holdings 8-K Report, Financial Results (Aug 1, 2023)

IQVIA Holdings Inc. (IQV) reported second-quarter 2023 results on August 1, 2023, as furnished in Exhibit 99.1. Revenue was $3,728 million, up 5.3 percent on a reported basis and 5.5 percent at constant currency. GAAP Net Income was $297 million and GAAP Diluted Earnings per Share was $1.59, while Adjusted Diluted Earnings per Share was $2.43, down 0.4 percent year-over-year. R&D Solutions (R&DS) contracted backlog reached $28.4 billion, growing 11.1 percent year-over-year, with a second-quarter book-to-bill ratio of 1.28x. CEO Ari Bousbib stated that commercial-side clients remain cautious and spending has not yet accelerated, while the clinical business is performing consistently with expectations. The company updated its full-year 2023 guidance, with revenue now expected between $15,050 million and $15,175 million, representing 4.4 to 5.3 percent reported growth. Adjusted EBITDA guidance is $3,600 million to $3,635 million, and Adjusted Diluted EPS guidance is $10.20 to $10.45. The company noted that step-up in interest rates and an increase in the UK corporate tax rate reduce year-over-year Adjusted EPS growth by approximately 12 percentage points. Third-quarter revenue is guided to $3,760 million to $3,810 million. Balance sheet metrics showed total debt of $13,777 million, net debt of $12,395 million, and a Net Leverage Ratio of 3.59x. The company repurchased $490 million of stock in the second quarter and $619 million year-to-date. On July 31, 2023, the board increased the repurchase authorization by $2 billion, bringing total remaining authorization to $2,736 million.

Aug 1, 2023 8-K

IQVIA Holdings 8-K Report, Material Agreement (May 23, 2023)

IQVIA Inc., a wholly owned subsidiary of IQVIA Holdings Inc., completed on May 23, 2023 the issuance and sale of two series of notes: $750,000,000 in gross proceeds of 5.700% senior secured notes due May 15, 2028, and $500,000,000 in gross proceeds of 6.500% senior notes due May 15, 2030. Both series were issued under separate indentures dated May 23, 2023, with U.S. Bank Trust Company, National Association, as trustee. The Senior Secured Notes are secured obligations of the Issuer, while the Senior Notes are unsecured. Interest on both series is payable semi-annually on May 15 and November 15, beginning November 15, 2023. The filing states that net proceeds will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the offering. The transaction therefore refinances revolving credit facility debt with longer-dated fixed-rate notes. The Company and certain subsidiaries of the Issuer are named as guarantors under the indentures. The Senior Secured Notes may be redeemed before April 15, 2028 subject to a customary make-whole premium, and at 100% of principal plus accrued interest thereafter. The Senior Notes may be redeemed before their maturity subject to a make-whole premium, with an equity claw redemption right available before May 15, 2026, and thereafter at a redemption premium declining from 3.250% to 0.000%. The full terms are set out in Exhibits 4.1 and 4.2, the indentures.

May 23, 2023 8-K

IQVIA Holdings 8-K Report, Corporate Update (May 19, 2023)

IQVIA Holdings Inc. (NYSE: IQV) disclosed on May 19, 2023 that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), is raising capital through a notes offering. On May 18, 2023, the Issuer entered into a purchase agreement for $750,000,000 of senior secured notes due 2028 bearing interest at 5.700% per annum and $500,000,000 of senior notes due 2030 bearing interest at 6.500% per annum. The company also announced an additional $250,000,000 of senior secured notes due 2028 as part of the pricing, bringing total gross proceeds to $1,250,000,000. The offering was upsized, which the filing attributes to strong demand. Proceeds will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the offering. The filing states the offering is expected to close on or about May 23, 2023, subject to customary closing conditions. The notes have not been registered under the Securities Act and are being offered to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S. For investors, the filing shows IQVIA refinancing existing revolver debt with longer-dated fixed-rate notes, with the senior secured tranche maturing May 15, 2028 and the senior notes maturing May 15, 2030. Interest on both tranches is payable semi-annually on May 15 and November 15, beginning November 15, 2023. The filing does not provide additional financial results or covenant details.

May 19, 2023 10-Q

IQVIA Holdings Quarterly Report for Q1 Ended Mar 31, 2023

IQVIA Holdings Inc. reported first-quarter 2023 revenues of $3,652 million, up $84 million, or 2.4%, from $3,568 million in the first quarter of 2022. Constant currency revenue growth was approximately $166 million, or 4.7%. Income from operations was $471 million, down from $495 million, and net income was $289 million, compared with $325 million a year earlier. Diluted earnings per share were $1.53, versus $1.68. Interest expense rose to $141 million from $86 million, driven by higher base rate interest costs on the floating rate debt portfolio and an increase in net debt. Restructuring costs were $17 million, up from $7 million. Research & Development Solutions was the main growth driver, with revenues of $2,026 million, up 4.8%, and segment profit of $428 million, up 6.7%. Contracted backlog in that segment rose to $27.9 billion from $27.2 billion at year-end 2022. Technology & Analytics Solutions revenues were essentially flat at $1,444 million, and segment profit fell 6.5% to $361 million. Contract Sales & Medical Solutions revenues declined 6.7% to $182 million. Operating cash flow was $417 million, down from $508 million, and the company repurchased $129 million of common stock during the quarter. Total indebtedness was $13,222 million at March 31, 2023, against cash of $1,494 million. On April 17, 2023, the company increased its senior secured revolving credit facility capacity by $500 million to $2,000 million. The filing also describes ongoing litigation, including a long-running dispute with Veeva Systems, in which the company says it intends to vigorously pursue its claims.

Apr 28, 2023